| External factors: | LGX818 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Melanoma |
| Experiment: | SA-β-gal activity assay//BrdU assay |
| Description: | A time-dependent increase in β-gal staining was noted in cells treated with 10 nM LGX818 for periods of up to 72 h compared with vehicle-treated (non-treated) cells. Consistently, LGX818 treatment led to a significant decrease in the percentage of BrdU-positive cells. Elevated SA-β-gal activity and reduced BrdU incorporation were also observed in LGX818-treated SK-MEL-24 cells. |
| Target gene: | P27//PRB |
| R-EF-Target gene: | Upregulation//Activation |
| Official symbol(s): | P27//PRB |
| Target gene experiment: | Western blot |
| Target gene description: | Immunoblot analysis demonstrated that A375 and G361 cells exhibited increased levels of p27KIP1 (CDK-inhibitory protein 1) protein 24 h after LGX818 treatment.We observed a remarkable decrease in the phosphorylation of Rb in A375 cells following a 24 h treatment with LGX818 and, to a lesser extent, in LGX818-treated G361 cells. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: